Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Aug 4, 2020, after the close
10-Q filed Aug 4, 2020, 35 days after period end · 0001558370-20-009154
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $16.02M | $10.41M | $1.79M | $0.00 |
| Net Income | -$17.58M | -$20.61M | -$25.56M | -$19.15M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.10 |
| -$0.12 |
| -$0.16 |
| -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
